1. Home
  2. MAT vs ACAD Comparison

MAT vs ACAD Comparison

Compare MAT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mattel Inc.

MAT

Mattel Inc.

HOLD

Current Price

$14.08

Market Cap

4.5B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.56

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAT
ACAD
Founded
1945
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
MAT
ACAD
Price
$14.08
$21.56
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$20.90
$30.55
AVG Volume (30 Days)
4.0M
1.4M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
0.20
0.02
Revenue
$5,347,623,000.00
$726,437,000.00
Revenue This Year
$5.92
$18.80
Revenue Next Year
$5.08
$11.70
P/E Ratio
$71.00
$1,086.08
Revenue Growth
N/A
40.45
52 Week Low
$14.03
$19.69
52 Week High
$22.48
$28.35

Technical Indicators

Market Signals
Indicator
MAT
ACAD
Relative Strength Index (RSI) 31.94 49.69
Support Level N/A $21.12
Resistance Level $15.38 $22.03
Average True Range (ATR) 0.44 0.62
MACD -0.10 0.05
Stochastic Oscillator 6.42 74.70

Price Performance

Historical Comparison
MAT
ACAD

About MAT Mattel Inc.

Mattel manufactures and markets toy products that are sold to its wholesale partners and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2025, with the remainder stemming from international markets.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: